CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:
Agilent beat Q2 expectations with revenue of $1.83B rising 10% Y/Y (+6.3% core), topping the $1.80B consensus, while adjusted EPS of $1.49 grew 14% Y/Y, beating the $1.41 forecast. Operating leverage was notable with adjusted operating margin expanding 130 bps Y/Y to 26.4%, driven by broad-based business growth across Americas (+11%) and Europe (+8%). We view the strong performance positively, supported by ongoing instrument replacement cycles and strength in Agilent's cancer diagnostics portfolio, with Life Sciences and Diagnostics sales rising 12% Y/Y. Management raised FY 26 guidance across all key metrics, increasing revenue guidance by 30 bps at the midpoint to $7.39-7.49B (up 6.3-7.8% reported, 4.5-6.0% core) and non-GAAP EPS guidance by $0.08 to $6.00-6.10. We expect continued momentum from pharma end markets (+6% core growth) and Applied Markets (+14% revenue growth), though academic/government weakness persists with core sales down 5% Y/Y on uncertain NIH funding policy.